Preclinical studies of a dual BCL-2/BCL-XL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity. Abstract 544
Home » Preclinical studies of a dual BCL-2/BCL-XL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity. Abstract 544
2014
Wang H, et al. Preclinical studies of a dual BCL-2/BCL-XL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity. Abstract 544. Eur J Cancer. vol. 50(Suppl 6), pp. 176-177, doi: 10.1016/S0959-8049(14)70670-7